Pregnancy complications of the antiphospholipid syndrome

被引:21
作者
Tincani, A
Balestrieri, G
Danieli, E
Faden, D
Lojacono, A
Acaia, B
Trespidi, L
Ventura, D
Meroni, PL
机构
[1] Spedali Civili Brescia, Serv Reumatol Allergol & Immunol Clin, I-25123 Brescia, Italy
[2] Spedali Civili Brescia, Div Ostet & Ginecol, I-25123 Brescia, Italy
[3] Clin Ostet & Ginecol Mangiagalli, Div Med Perinatale, Milan, Italy
[4] Univ Milan, IRCCS Ist Auxol Italiano, Dipartimento Med Interna, Unita Allergol & Immunol Clin, Milan, Italy
关键词
antiphospholipid antibodies; pregnancy; fetal loss; pre-eclampsia; PLACENTAL ANTICOAGULANT PROTEIN; LOW-DOSE ASPIRIN; ANTICARDIOLIPIN ANTIBODIES; ANTI-BETA(2)-GLYCOPROTEIN I; CONTROLLED-TRIAL; FETAL LOSS; WOMEN; HEPARIN; PREVALENCE; ASSOCIATION;
D O I
10.1080/0891693031000067278
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Starting from their first description, antiphospholipid antibodies (aPL) were associated with repeated miscarriages and fetal losses. Other complications of pregnancy like preterm birth, with pre-eclampsia or severe placental insufficiency were also frequently reported and are included in the current classification criteria of the antiphospholipid syndrome (APS). The titre, the isotype of the antibodies or their antigen specificity may be important in the risk level determination. Some of the difference in the reported results can be explained by the poor standardization achieved in aPL testing or by the not univocal classification of pregnancy complications. The pathogenesis of pregnancy failures is linked to the thrombophilic effect of aPL but also to different mechanisms including a direct effect of antibodies on the throphoblast differentiation and invasion. The study of experimental animal models provided sound evidence of the pathogenic role of aPL both in lupus prone and naive mice. The definition of APS as a condition linked to high obstetric risk and the application of an effective therapy have completely changed the prognosis of pregnancy in these patients. In fact, despite the high number of complications and preterm delivery, today a successful outcome can be achieved in the large majority of the cases.
引用
收藏
页码:27 / 32
页数:6
相关论文
共 63 条
[11]   Is interleukin-3 important in antiphospholipid anti body-mediated pregnancy failure? [J].
Chamley, LW ;
Konarkowska, B ;
Duncalf, AM ;
Mitchell, MD ;
Johnson, PM .
FERTILITY AND STERILITY, 2001, 76 (04) :700-706
[12]   REPEATED FETAL LOSSES ASSOCIATED WITH ANTIPHOSPHOLIPID ANTIBODIES - A COLLABORATIVE RANDOMIZED TRIAL COMPARING PREDNISONE WITH LOW-DOSE HEPARIN TREATMENT [J].
COWCHOCK, FS ;
REECE, EA ;
BALABAN, D ;
BRANCH, DW ;
PLOUFFE, L .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1992, 166 (05) :1318-1323
[13]  
Di Simone N, 2000, ARTHRITIS RHEUM-US, V43, P140, DOI 10.1002/1529-0131(200001)43:1<140::AID-ANR18>3.0.CO
[14]  
2-P
[15]   Anti-beta 2 glycoprotein I antibodies in a general obstetric population: Preliminary results on the prevalence and correlation with pregnancy outcome. Anti-beta 2 glycoprotein I antibodies are associated with some obstetrical complications, mainly preeclampsia-eclampsia [J].
Faden, D ;
Tincani, A ;
Tanzi, P ;
Spatola, L ;
Lojacono, A ;
Tarantini, M ;
Balestrieri, G .
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1997, 73 (01) :37-42
[16]   Antiphospholipid syndrome in pregnancy: A randomized, controlled trial of treatment [J].
Farquharson, RG ;
Quenby, S ;
Greaves, M .
OBSTETRICS AND GYNECOLOGY, 2002, 100 (03) :408-413
[17]  
FISHMAN P, 1995, J RHEUMATOL, V22, P1086
[18]  
Fishman P, 1996, AM J REPROD IMMUNOL, V35, P80
[19]   PREVENTION OF FETAL LOSS IN EXPERIMENTAL ANTIPHOSPHOLIPID SYNDROME BY INVIVO ADMINISTRATION OF RECOMBINANT INTERLEUKIN-3 [J].
FISHMAN, P ;
FALACHVAKNINE, E ;
ZIGELMAN, R ;
BAKIMER, R ;
SREDNI, B ;
DJALDETTI, M ;
SHOENFELD, Y .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (04) :1834-1837
[20]   Obstetric implications of antiphospholipid antibodies: Pregnancy loss and other complications [J].
Geis, W ;
Branch, DW .
CLINICAL OBSTETRICS AND GYNECOLOGY, 2001, 44 (01) :2-10